.
Discovery Experimental & Development Inc. (DEDI)
This website was written by:
James Kimball
Please Select A Category
Eldepryl was approved by the FDA in 1989 as a drug not to be used by itself, but to be used in combination with another prescription drug Levodopa in the treatment of only one disease, Parkinson's Disease.
To obtain FDA approval Mylan Laboratories, a large generic drug manufacturer formed a paper corporation called Somerset Pharmaceuticals. Mylan Laboratories held a high percentage of stock in a company which had nothing other than a SelegilineHydrochloride tablet that it purchased from Hungary.
Mylan had its paper company Somerset make a deal with a Dr. Ira Shoulson to conduct studies and trials to gain FDA approval for this paper company, Somerset. This was in an effort to make billions of dollars by price gouging the public with a product they all knew didn't work. Dr. Ira Shoulson picked a sophisticated name for his trials calling them the Data Top Study. This Data Top Study, controlled by Dr. Shoulson and Somerset via Mylan Pharmaceutical was rigged to gain FDA approval. It is assumed additionally that Mylan stock and Bolar Pharmaceutical stock, another pharmaceutical company that had a large portion of Somerset's stock paid off FDA employees for Eldepryl's approval.
Bolar Pharmaceuticals, Inc. had already been caught rigging generic drug approvals and bribing FDA officials.
How The Trials With Eldepryl Were Rigged
Dr. Shoulson was in charge of administering Eldepryl to groups of people which were afflicted with terminal Parkinson's disease.
Shoulson was to give one group Eldepryl; a pill made in Hungary, which contained an active chemical ingredient Selegiline HCL and another group a fake pill, containing no Selegiline HCL. Shoulson was to compare the two groups to see if the Parkinson's patients receiving the Eldepryl had more improvement than the patients taking the fake pill without Selegiline HCL in it.
Dr. Shoulson rigged the trials to show that the groups receiving Eldepryl improved while the groups receiving nothing got worse.
Meanwhile Somerset Pharmaceuticals and its owners, Mylan and Bolar Pharmaceuticals were rigging the testing of Eldepryl. Somerset had to reveal "all" the ingredients within their active ingredient Selegiline HCL from Hungary.
Somerset did reveal the Selegiline HCL from Hungary was contaminated with methamphetamine, which the FDA said was OK. Somerset Pharmaceuticals did not reveal an unknown contaminate that was within their Selegiline HCL from Hungary. Somerset made sure the test results they submitted to the FDA and its affiliate, the US Pharmacopoeia (USP) did not reveal the unknown contaminate within their Hungarian product.
The FDA Approves Eldepryl In 1989 To Only Be Used With Another Product And Only For Parkinson's Disease
Someone at the FDA either knew the trials were rigged or knew the Data Top Studies controlled by Dr. Shoulson were not conclusive enough, to reveal much benefit for people affected with Parkinson's Disease.
The FDA should " NOT" have approved the contaminated product at all. However, the FDA being what they are, approved Eldepryl to be used only with another FDA approved prescription drug for Parkinson's called Levodopa.
Levodopa Has Serious Side Effects Up To DEATH!
Levodopa was approved by the FDA as a prescription drug for people afflicted with Parkinson's Disease.
Kimball and DEDI extensively researched the effects of Levodopa in the treatment of patients afflicted with Parkinson's Disease which in the past had always proven to be terminal.
After reviewing Levodopa's use worldwide, it was concluded by DEDI that Parkinson's sufferers using Levodopa in the US, positively died faster than if they never used Levodopa at all.
Levodopa clearly does not slow down or stop the progression of Parkinson's. The way Levodopa is allowed by the FDA to be used by doctors within the United States clearly appears to shorten the life of Parkinson's sufferers.
How does Levodopa work? Levodopa only masks the symptoms of Parkinson's disease patients. Parkinson sufferers have serious mobility problems and the administration of Levodopa gives them back their mobility for the short term.
As long as the people keep taking Levodopa most symptoms are hidden. However much like an addictive narcotic, the dosages of Levodopa have to be continually increased in order to mask the immobility of the disease. This regiment in the US continues until the patient dies of Parkinson's or too much Levodopa.
Most doctors in Europe do not administer Levodopa in such a non-concerned manner. Also, doctors in Europe, Kimball spoke with, advised their Parkinson's patients of the detriments of using Levodopa.
In Europe most doctors Kimball spoke with advised their Parkinson's patients to use Levodopa when absolutely necessary to function and only for a very short term and in a sporadic manner. On average it clearly appeared people afflicted with Parkinson's on a sporadic regiment lived longer than people in the US on a constant regiment.
The best way to explain how Levodopa works is to say Levodopa is a man-made (synthetic) attempt at making a chemical the body produces called dopamine. Because Parkinson's sufferers have a shortage of this chemical, dopamine, in the brain, scientists concluded that if they could come up with a synthetic dopamine, it would end Parkinson's disease. Their theory was commendable, however the product they came up with was a similar product to dopamine that the body produces, not the same.
When Levodopa is administered in varying amounts, it appears the synthetic product passes the blood bran barrier and settles within the same region of the brain that the body's own natural dopamine rests. Thus, the depleted natural chemical dopamine, which is causing the Parkinson's disease, is now replenished by the man-made version, Levodopa.
The brain's natural dopamine appears to be compatible to the man made synthetic and the now combined dopamine level is increased. The Parkinson's immobility symptoms are dramatically improved, however, rarely disappear entirely. Mobility is dramatically improved. This appears to be a very good regiment to use only when absolutely needed, for a very short term.
The very obvious problem with the continuous use of Levodopa or synthetic dopamine is: the 2 chemicals are not the same and although they seem to work together to an extent, Levodopa is not dopamine, nor can it take its place independently.
Most scientists and knowledgeable ethical doctors are aware that when a man-made duplicate substance is given, over a long period of time, to increase a substance the body already produces, the body tends to stop producing that substance, sometimes entirely.